Epileptic syndromes: From clinic to genetic

Abbas Tafakhori1, Vajiheh Aghamollaii2, Sara Faghihi-Kashani3, Payam Sarraf1, Laleh Habibi4

1 Department of Neurology, School of Medicine, Imam Khomeini Hospital AND Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Neurology, School of Medicine, Roozbeh Hospital AND Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Keywords
Epilepsy, Genetic, Inheritance, Chromosomal Abnormalities, Mutation

Abstract
Epilepsy is one of the most common neurological disorders. Studies have demonstrated that genetic factors have a strong role in etiology of epilepsy. Mutations in genes encoding ion channels, neurotransmitters and other proteins involved in the neuronal biology have been recognized in different types of this disease. Moreover, some chromosomal aberration including ring chromosomes will result in epilepsy. In this review, we intend to highlight the role of molecular genetic in etiology of epilepsy syndromes, inspect the most recent classification of International League against Epilepsy and discuss the role of genetic counseling and genetic testing in management of epilepsy syndromes. Furthermore, we emphasize on collaboration of neurologists and geneticists to improve diagnosis and management.

Introduction

Epilepsy
Definition
“Epilepsy” is derived from the Latin term meaning, “to be attacked.” In medicine, epilepsy is defined as recurring episodes of seizures due to excessive and abnormal synchronous neural activity of the cerebral cortex, which could be induced by cellular or molecular defects in cerebral tissues. In cases of an altered endocrine or metabolic state, it would be categorized as structural/metabolic epilepsy. However, on occasions the underlying disorder could not be recognized, and it would be classified under unknown category. Epilepsies attributed to known genetic disorders are classified as genetic epilepsies (refer to the next section).

Classification
Based on the 2010 report of International League Against Epilepsy (ILAE),9 the etiology of epileptic seizures is divided into three major classes as discussed below.

Genetic epilepsy: this category (previously known as idiopathic) implies epileptic disorders that are a direct consequence of either known single gene defects or complex inheritances in which the epilepsy is the essential symptom. Nonetheless, the
contribution of environmental factors in disease expression cannot be disregarded.\textsuperscript{2,9} The recent alternation of "idiopathic" to "genetic" has the advantage of highlighting the genetic predisposition, and it no longer conflate other concepts (e.g., prognosis). Most cases display clinical features during childhood or adolescence. Although some suffers from a variety of subtle cognitive and behavioral challenges, the affected patients may have normal intelligence, and EEG might also show generalized discharges.\textsuperscript{9,10} Genetic epilepsy is further divided into generalized and partial epilepsy. Childhood absence epilepsy, juvenile myoclonic epilepsy and epilepsy with grand-mal seizures on awakening are examples of genetic generalized and benign focal epilepsy of children is an instance of partial genetic epilepsy.\textsuperscript{2,9}

Structural/metabolic epilepsy: Epilepsies classified under this category (previously known as symptomatic) require specific structural or metabolic defects that have been demonstrated to be associated with considerably higher risk of epilepsy. Genetic abnormalities, including mutations and chromosomal abnormalities (e.g., tuberous sclerosis) might be the origin of this category of epilepsy with a particular metabolic or structural disorder inserted between genetic defect and occurrence of epilepsy.\textsuperscript{9}

Unknown epilepsy: this category has replaced the previous classification known as cryptogenic. It should be noted that this category contains epileptic disorders, which the underlying cause is not yet determined and could be a consequence of a genetic or separate defect.\textsuperscript{9,11} Considering the enhancement of genetic methods and improved neuroimaging techniques, the prevalence of unknown epilepsy is decreasing.\textsuperscript{11}

**Role of genetic in etiology of epilepsy**

Since establishment of Mendelian Inheritance laws in 1865, modern science launched numerous investigations to discover the role of genetics in pathology of human diseases. The recognized scholarly debate of nature versus nurture, a popular concept in epilepsy disorders, have influenced research agendas for a century and many pioneers tried to unveil this mystery by studying monozygote (MZ) vs. dizygote twins (DZ).\textsuperscript{12-15} These approaches provide an opportunity to decompose the variables into genetic and environmental factors. Identical twins share about 100% of their genes, while fraternal twins share nearly 50%, and both share many aspects of the environment by virtue of being born in the same place and time. Detection of a particular trait to be substantially more common in MZ twins implicates the importance and strength of genetic determinants in expression of the specific trait.\textsuperscript{16}

Concordance of epilepsy has been estimated 62% in MZ pairs compared with 18% in DZ twins.\textsuperscript{13} Large twin population studies suggest a higher rate of epilepsy syndromes in MZ pairs,\textsuperscript{13-15} specifically generalized epilepsy.\textsuperscript{13} These findings propose the involvement of syndrome-specific genetic determinants in pathology of this group of disorders. It has been estimated that genetic epilepsy affects 0.3-0.5% of general population.\textsuperscript{1,17} Children of one parent with genetic epilepsy have a 4-6% risk, while children of both parents with genetic epilepsy have a 12-20% risk.\textsuperscript{1}

Recent reports have highlighted the importance of genetic predisposition in epilepsy syndromes, as ILAE has altered the previous "idiopathic" category to "genetic" and has approved of genetic testing for patients and families affected by epileptic syndromes including X-linked infantile spasm, Dravet syndrome, Ohtahara syndrome, and early-onset absence epilepsy.\textsuperscript{18} Furthermore, the new approaches to sequence DNA is revealing specific gene defects and linking them to distinct clinical features of genetic epilepsies.\textsuperscript{8}

Genetic epilepsies could further divide into four subgroups according to the mechanism of inheritance: (1) genetic epilepsy with Mendelian inheritance, (2) epilepsies with complex inheritance, (3) genetic epilepsies associated with cytogenetic abnormalities and (4) Mendelian disorders in which epilepsy is one of the manifestations. The former class is thought to account for a small number of epilepsies, and the disease occurrence could be tracked through generation. A proper pedigree analysis will affirm whether the phenotype is dominant or recessive, autosomal or X-linked (Figure 1).\textsuperscript{11} Epilepsies with complex inheritance are believed to be involved in 50% of epilepsies.\textsuperscript{11} Though familial aggregation is seen through generations, the mode of inheritance cannot easily be identified.

Detection of a specific chromosomal abnormality (either structural or numerical) would be categorized under genetic epilepsies with cytogenetic abnormalities.\textsuperscript{11} This subgroup is mostly associated with other neurological disorders and facial anomalies.

Mendelian disorders in which epilepsy is one of the manifestations indicate multisystem disorders with epilepsy as one of the characteristics. These syndromes include neurocutaneous and neurodegenerative disorders and a cluster of metabolic diseases.\textsuperscript{11} Thus, the genetic counselor might be able to assess these syndromes. However, such disorders could hardly be considered an epileptic disease since epilepsy occurs as a secondary symptom.
The following section is dedicated to reviewing the role of chromosomal abnormalities and gene mutations in etiology of epileptic syndromes with some examples. We are referring interested readers for a complete list of genes mutated in epilepsies to two reviews written by Garofalo et al. and Kaneko et al.

**Chromosomal aberrations**

Chromosomal aberration is characterized by atypical number or structural abnormality of at least one chromosome that usually leads to genetic disorders. In numerical group, aneuploidy is usually due to abnormal gametogenesis in parents. Considering aneuploidy is accompanied with gaining or losing considerable amount of genetic materials, apart from sex chromosome disorders it is a fatal. However, there are few cases of live birth. These patients usually suffer from facial dysmorphisms and mental retardation as well as seizure. Conventional karyotyping could easily identify numerical chromosomal aberrations.

There are several forms of structural chromosomal abnormalities including deletion, duplication and translocation of portion of a chromosome. These defects are not generally fatal, and newborns with structural abnormalities may have developmental delay and facial dysmorphism. Epilepsy is one of the widespread features in this group of anomalies. Ring chromosomes detection might help discovering genetic epilepsy. A ring chromosome is usually formed through breakage of both ends of the chromosome and fusion of arms. Back et al. have reported a phenotypically normal woman with ring chromosome 20 who had two children suffering from mental retardation, behavioral disorder, and epilepsy. In addition, EEG of epileptic patients with
ring chromosome 20 has a distinct feature of prolonged high-voltage slow waves and seizures are resistant to medications. Ring chromosome 14 has also been reported to be resistant to antiepileptic therapy. The onset of epilepsy in this chromosomal disorder is often during the first year, mental retardation would be a constant character and the majority of cases have dysmorphic facial features. EEG frequently reveals focal abnormality.

Chromosome 6q deletion (Long arm of chromosome 6) and chromosome 22q duplication have been shown to be associated with dysmorphic facial abnormalities, mental retardation and epilepsy.

As a result of high-resolution karyotyping, many epileptic seizures have been linked to chromosomal abnormalities. Aberrations such as microdeletions and microduplications (microchromosomal defects) that could not be detected by conventional karyology might be identified by molecular cytogenetic approaches including comparative genomic hybridization (CGH) array and multiplex ligation-dependent probe amplification (MLPA). Exploring the nature of the human genome with high repetitive DNA sequences lead to discovering recurrent rearrangements of regions in some chromosomes such as 15q and 16p that are involved in epilepsy could result in recurrent heritable microdeletions and microduplications.

**Gene mutations**

In addition to chromosomal abnormalities, gene mutations also could be associated with epilepsy syndromes. A good example would be genes encoding ion channel subunits. Excitatory or inhibitory neurotransmitters in central nervous system have also been recognized in Mendelian forms of epilepsy and thus, following simple Mendelian mode of inheritance. Genetic counseling could help identifying these disorders through a prodigy and risk of disease could be estimated for the next generation.

**CHRNA4** gene encodes neural acetylcholine receptor subunit α4. It was the first gene to be associated with epilepsy syndromes. Mutation in this gene has been linked to Autosomal dominant nocturnal frontal lobe epilepsy. KCNQ2 and KCNQ3 genes that encode voltage-gated potassium channels were identified in families affected with benign familial neonatal seizures.

At least 37 genes for generalized myoclonic epilepsy and febrile seizures, 47 genes for symptomatic (structural/metabolic) epilepsy and 30 genes for epileptic encephalopathies have been recognized. In a recent study of pediatric patients affected with infantile spasms and Lennox-Gastaut syndrome, two forms of epileptic encephalopathies, and their parents, researchers found 329 de novo mutations. These mutations are significantly more prominent in genes sets regulated by fragile X protein. Mutation of fragile X protein has been extensively discussed in autism spectrum disorders as it is the most widespread single-gene cause of autism. Further genetic defects involved in epileptic encephalopathies include MTOR, GABRA1 and FLNA.

Mutation in SCN1A, a gene encoding voltage-gated sodium channel, has been demonstrated to be involved in SCN1A gene. As a result of high-resolution karyotyping, many epileptic seizures have been linked to chromosomal abnormalities. Aberrations such as microdeletions and microduplications (microchromosomal defects) that could not be detected by conventional karyology might be identified by molecular cytogenetic approaches including comparative genomic hybridization (CGH) array and multiplex ligation-dependent probe amplification (MLPA). Exploring the nature of the human genome with high repetitive DNA sequences lead to discovering recurrent rearrangements of regions in some chromosomes such as 15q and 16p that are involved in epilepsy could result in recurrent heritable microdeletions and microduplications.

**Gene mutations**

In addition to chromosomal abnormalities, gene mutations also could be associated with epilepsy syndromes. A good example would be genes encoding ion channel subunits. Excitatory or inhibitory neurotransmitters in central nervous system have also been recognized in Mendelian forms of epilepsy and thus, following simple Mendelian mode of inheritance. Genetic counseling could help identifying these disorders through a prodigy and risk of disease could be estimated for the next generation.

**CHRNA4** gene encodes neural acetylcholine receptor subunit α4. It was the first gene to be associated with epilepsy syndromes. Mutation in this gene has been linked to Autosomal dominant nocturnal frontal lobe epilepsy. KCNQ2 and KCNQ3 genes that encode voltage-gated potassium channels were identified in families affected with benign familial neonatal seizures.

At least 37 genes for generalized myoclonic epilepsy and febrile seizures, 47 genes for symptomatic (structural/metabolic) epilepsy and 30 genes for epileptic encephalopathies have been recognized. In a recent study of pediatric patients affected with infantile spasms and Lennox-Gastaut syndrome, two forms of epileptic encephalopathies, and their parents, researchers found 329 de novo mutations. These mutations are significantly more prominent in genes sets regulated by fragile X protein. Mutation of fragile X protein has been extensively discussed in autism spectrum disorders as it is the most widespread single-gene cause of autism. Further genetic defects involved in epileptic encephalopathies include MTOR, GABRA1 and FLNA.

Mutation in SCN1A, a gene encoding voltage-gated sodium channel, has been demonstrated to be involved in SCN1A gene. As a result of high-resolution karyotyping, many epileptic seizures have been linked to chromosomal abnormalities. Aberrations such as microdeletions and microduplications (microchromosomal defects) that could not be detected by conventional karyology might be identified by molecular cytogenetic approaches including comparative genomic hybridization (CGH) array and multiplex ligation-dependent probe amplification (MLPA). Exploring the nature of the human genome with high repetitive DNA sequences lead to discovering recurrent rearrangements of regions in some chromosomes such as 15q and 16p that are involved in epilepsy could result in recurrent heritable microdeletions and microduplications.
Myoclonus epilepsy and ragged-red fibers are a rare mitochondrial disorder involving usually mutation of MT-TK gene located on mitochondrial DNA. It would lead to progressive neurological symptoms, including blindness and myoclonic epilepsy. Mitochondrial pattern of inheritance is relatively complex (Figure 2) as maternal mutated mitochondria affects zygote formation.

![Figure 2](image.png)

Each children receive mutated mtDNA from mother and may be affected regarding the amount of mutated mtDNA in their cells

**Figure 2.** Transmission of mitochondrial DNA mutation in a hypothetical pedigree. This mode of inheritance is categorized as non-mendelian transmission because the mutated gene is not located in nuclear DNA. Mitochondria and its DNA (mtDNA) will transmit to next generation through oocyte cytoplasm so just mutated mtDNA from mother could cause the disease. Since, we have too many mitochondria and copies of mtDNA in a cell, the presence of disease and severity of its phenotype will be dependent on the amount of mutated mtDNA inside individual’s cells. Heteroplasmy means both mutated and non-mutated mtDNA is present in a cell. Homoplasmy means the whole mtDNAs in a cell are mutated or non-mutated.

Malformation of cortical development disorders represents a major spectrum of mental disabilities with severe epilepsies caused by defective neuronal migration. Mutation of LISI gene encoding microtubule-associated protein is one of the several genetic defects linked to these disorders. Lissencephaly with X-link gene mutation (xLIS) is another defective neuronal migration disorder that result in the lack of cerebral folds. Both genetic and non-genetic factors (e.g. viral infections of the fetus) are involved in etiology of these disorders.

The introduction of new techniques of DNA sequencing has helped identifying point mutations, small insertions, and deletions.

**Genetic counseling and genetic testing in epilepsy management**

Epilepsy is a multifactorial disease, and both genetic and environmental components are involved in etiology (Table 1). Various investigations, particularly twin studies, have contributed to detection the role of genetic elements in epilepsy syndromes. These findings will help predicting the clinical symptoms of the affected individual through genotype-phenotype correlation and conduct follow-up of high-risk pregnancies or an infant born in a family with increased rate of epilepsy. It will also aid the clinician in anticipating the clinical features in advance and manage in accordance.

Detection of specific genetic disorders will improve our understanding of the inheritance pattern. Thus, genetic counseling could better help families by estimating the risk of disease in next generation and family members of epileptic probands, who might be at greater risk for epilepsy syndromes. Interestingly, the same phenotype of epilepsy in different members of a pedigree could be due to different genetic defects. Consanguineous marriage will increase the risk of epilepsy syndrome, especially childhood onset of epilepsy and is a remarkable challenge for clinicians and geneticists in societies where it is a common tradition.

**Conclusion**

We emphasize on cooperation of clinicians (particularly neurologist) and medical genetic experts in eastern societies like Iran, where consanguineous marriage is a common practice. This assistance is highlighted in high-risk families. It should be noted that prior to any genetic testing, patient and family members should be pre-tested in genetic counseling sessions.

The genetic testing now commercially available for epilepsy includes analysis of 70 genes for detection of point mutations and deletion/duplications using DNA sequencing, CGH array, and MLPA techniques. The specimen used for genetic testing could be whole blood or any other body tissue appropriate for DNA extraction, for example, amniotic fluid, and chorionic villi samples are required for prenatal diagnosis.

Hence, collaboration of neurologist with geneticist in the case of genetic epilepsy will help the diagnosis and in some cases will improve management.

**Conflict of Interests**

The authors declare no conflict of interest in this study.

**Acknowledgments**

We appreciate the help of our department’s staff and supports of the Tehran University of Medical Sciences, Iran.

**How to cite this article:** Tafakhori A, Aghamollaii V, Faghihi-Kashani S, Sarraf P, Habibi L. Epileptic syndromes: From clinic to genetic. Iran J Neurol 2015; 14(1): 1-7.
### Table 1. Summary of genetic abnormalities in different forms of epilepsies

| Epilepsy classification | Genetic abnormality | Genetic features | Example | Genetic test |
|-------------------------|---------------------|-----------------|---------|-------------|
| Epilepsy with mendelian inheritance | Specific gene mutation | Determined mode of inheritance | Generalized myoclonic epilepsy and febrile seizures | DNA sequencing, exom sequencing |
| Epilepsy with complex inheritance | Hard to find | Mode of inheritance could not be determined | Different tests | |
| Epilepsy with chromosomal abnormality | Chromosomal aberrations | Usually sporadic | Ring chromosome 20, deletion of 6q, duplication 22q | Karyotyping, CGH, MLPA |
| Epilepsy associated with other mendelian disease | Specific gene mutation, mtDNA mutation | Determined mode of inheritance, sporadic | Lafora body disease, Neural ceroid lipofuscinosis, MERRF | DNA sequencing, exom sequencing |

MERRF: Myoclonus epilepsy and ragged-red fibers; CGH: Comparative genomic hybridization; MLPA: Multiplex ligation-dependent probe amplification

### References

1. Dekker PA. Epilepsy: A Manual for Medical and Clinical Officers in Africa. Geneva, Switzerland: World Health Organization; 2002.
2. Berg AT, Millichap J. The 2010 revised classification of seizures and epilepsy. Continuum (Minneap Minn) 2013; 19(3 Epilepsy): 571-97.
3. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures. Neurology 1982; 32: 1217-22.
4. Beletsky V, Mirsattari SM. Epilepsy, mental health disorder, or both? Epilepsy Res Treat 2012; 2012: 163731.
5. Engel J. The epilepsies. In: Wyngarden J, Smith L, Bennett C, Editors, Cecil's Textbook of Medicine, 19th ed. Philadelphia, PA: WB Saunders; 1992. p. 2202-13.
6. Noachtar S, Remi J. The role of EEG in epilepsy: a critical review. Epilepsy Behav 2009; 15(1): 22-33.
7. Benbadis S. The differential diagnosis of epilepsy: a critical review. Epilepsy Behav 2009; 15(1): 15-21.
8. Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes And Their Treatment: Based on the New Ilae Diagnostic Scheme. Oxfordshire, UK: Bladon Medical Pub p. 278; 2002.
9. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BO, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51(4): 796-803.
10. Tafakhori A, Shokri S, Mirzaei B. The clinical impact of epilepsy genetics. J Neurol Neurosurg Psychiatry 2001; 70(4): 428-30.
11. Lennox WG. The heredity of epilepsy as told by relatives and twins. J Am Med Assoc 1951; 146(6): 529-36.
12. Berkovic SF, Cottrell KJ. Epilepsy syndromes: a primer for geneticists. Epilepsia 1998; 39(4): 347-55.
13. Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsy syndromes with genetic basis: a clinical approach. Brain 2000; 123(Pt 6): 1195-213.
14. Harvald B, Hauge M. Hereditary factors elucidated by twin studies. In: Van Gündüz Neel J, Editor. Genetics and the epidemiology of chronic diseases. Washington, DC: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Division of Chronic Diseases; 1965. p. 617-48.
15. Sillanpää M, Koskenvuo M, Romanov K, Kaprio J. Genetic factors in epileptic seizures: evidence from a large twin population. Acta Neurol Scand 1991; 84(6): 523-6.
16. Bouchard TJ, Propping P. Twins as a tool of behavioral genetics: report of the Dahlem Workshop on What Are the Mechanisms Mediating the Genetic and Environmental Determinants of Behavior? Twins as a Tool of Behavioral. New Jersey, NJ: J. Wiley; 1993. p. 326.
17. Baraïter M. The genetics of neurological disorders. 2nd ed. Oxford, UK: Oxford University Press; 1990. p. 113.
18. Ottman R, Hørose S, Jain S, Lerre H, Lopes-Cendes I, Noebels JL, et al. Genetic testing in the epilepsies–report of the ILAE Genetics Commission. Epilepsia 2010; 51(4): 655-70.
19. Kaneko S, Wada K. Molecular genetic studies of epilepsies. No To Shinkei 1998; 50(12): 1071-7.
20. Garafolo S, Cornacchione M, Di CA. From genetics to genomics of epilepsy. Neurol Res Int 2012; 2012: 876254.
21. Kaneko S, Okada M, Iwasa H, Yamakawa K, Hørose S. Genetics of epilepsy: current status and perspectives. Neurosci Res 2002; 44(1): 11-30.
22. Luthardt FW, Krüeting K. Epileptogenic Chromosomal Syndromes and Genetic Disease [Online]. [cited 2001]; Available from: URL: http://www.els.net/WileyCDA/ElsArticle/re fId-a0001446.html
23. Langer JC. Prenatal diagnosis of congenital anomalies. What can and should be done? Can Fam Physician 1993; 39: 595-602.
24. Kumada T, Ito M, Miyajima T, Fuji T, Okuno T, Go T, et al. Multi-institutional study on the correlation between chromosomal abnormalities and epilepsy. Brain Dev 2005; 27(2): 127-34.
25. Sorge G, Sorge A. Epilepsy and chromosomal abnormalities. Ital J Pediatr 2010; 36: 36.
26. O'Connor C. Karyotyping for chromosomal abnormalities. Nature Education 2008; 1(1): 27.
27. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skag J, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82(2): 477-88.
28. Inoue Y, Fujiwara T, Matsuda K, Kubota H, Tanaka M, Yagi K, et al. Ring chromosome 20 and nonconvulsive status epilepticus. A new epileptic syndrome. Brain 1997; 120 (Pt 6): 939-53.
29. Atkins L, Miller WL, Salam M. A ring-20 chromosome. J Med Genet 1992; 9(3): 377-80.
30. Faed M, Morton HG, Robertson J. Ring F chromosome mosaicism (46,XY,20r-46,XY) in an epileptic child without apparent haematological disease. J Med Genet 1972; 9(4): 470-3.
31. Back E, Voiculescu I, Brunger M, Wolf G. Familial ring (20) chromosomal mosaicism. Hum Genet 1989; 83(2): 148-54.
32. Specchio N, Trivisano M, Serino D, Cappelletti S, Carotenuto A, Claps D, et al. Epilepsy in ring 14 chromosome syndrome. Epilepsy Behav 2012; 25(4): 585-92.
33. Vignoli A, Sconavacca GF, Peron A, La BF, Canavini MP. Interstitial 6q microdeletion syndrome and epilepsy: a new patient and review of the literature. Am J Med Genet A 2013; 161A(8): 2009-15.
34. Han K, Holder JL, Schaaf CP, La H, Chen H, Kang H, et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013; 503(7474): 72-7.
35. Battaglia A, Guerini R. Chromosomal disorders associated with epilepsy. Epileptic
Epileptic syndromes

36. Singh R, Gardner RJ, Crossland KM, Scheffer IE, Berkovic SF. Chromosomal abnormalities and epilepsy: a review for clinicians and gene hunters. Epilepsia 2002; 43(2): 127-40.

37. Zuberi SM. Chromosome disorders associated with epilepsy. Handb Clin Neurol 2013; 111: 543-8.

38. Mulley JC, Meford HC. Epilepsy and the new cytogenetics. Epilepsia 2011; 52(3): 423-32.

39. Mefford HC, Mulhe H, Ostertag P, von SS, Buyssse K, Baker C, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet 2010; 6(5): e1000962.

40. Bedoyan JK, Kumar RA, Sudi J, Silverstein F, Ackley T, Iyer RK, et al. Duplication 16p11.2 in a child with infantile seizure disorder. Am J Med Genet A 2010; 152A(6): 1567-74.

41. Cardoso C, Boys A, Parrini E, Mignon-Ravix C, McMahon JM, Khantane S, et al. Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology 2009; 72(9): 784-92.

42. Mulley JC, Nelson P, Guerrero S, Dibbens L, Iona X, McMahon JM, et al. A new molecular mechanism for severe myoclonic epilepsy of infancy: exonic deletions in SCN1A. Neurology 2006; 67(6): 1094-5.

43. Cossette P. Channelopathies and juvenile myoclonic epilepsy. Epilepsia 2010; 51(Suppl 1): 30-2.

44. Jurkat-Rott K, Lerche H, Weber Y, Lehmann-Horn F. Hereditary channelopathies in neurology. Adv Exp Med Biol 2010; 686: 305-34.

45. Werner FM, Covens R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy: a focus on antiepileptic drugs.Curr Med Chem 2011; 18(32): 4933-48.

46. Jefferys JG. Advances in understanding basic mechanisms of epilepsy and seizures. Seizure 2010; 19(10): 638-46.

47. Scharffman HE. The neurobiology of epilepsy. Curr Neurol Neurosci Rep 2007; 7(4): 348-54.

48. Anand R, Lindstrom J. Chromosomal localization of seven neuronal nicotinic acetylcholine receptor subunit genes in humans. Genomics 1992; 13(4): 962-7.

49. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11(2): 201-3.

50. Hirose S, Iwata H, Akiyoshi H, Kobayashi K, Ito M, Wada K, et al. A novel mutation of CHRNA4 responsible for autosomal dominant nocturnal frontal lobe epilepsy. Neurology 1999; 53(8): 1749-53.

51. Biwert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998; 279(5349): 403-6.

52. Singh NA, Charlier C, Stauffer D, Dupont BR, Leach RJ, Melis R, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18(1): 25-9.

53. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, et al. De novo mutations in epileptic encephalopathies. Nature 2013; 501(7466): 217-21.

54. Goodlin-Jones BL, Tassome F, Gane LW, Hagerman RJ. Autistic spectrum disorder and the fragile X premutation. J Dev Behav Pediatr 2004; 25(6): 392-8.

55. Akiyama M, Kobayashi K, Ohtsuka Y. Dravet syndrome: a genetic epileptic disorder. Acta Med Okayama 2012; 66(5): 369-76.

56. Dibbens LM, Tarpey PS, Hynes K, Bayly MA, Scheffer IE, Smith R, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 2008; 40(6): 776-81.

57. Marin I, Mei D, Tomudo T, Ferrari AR, Buti D, Dravet C, et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A seizures. Epilepsia 2007; 48(9): 1678-85.

58. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Vitanova K, Miao J, et al. Mutations in the gene encoding cystatin B in progressive myoclonic epilepsy (PME1). Science 1996; 271(5256): 1731-4.

59. Norio R, Koskiniemi M. Progressive myoclonic epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979; 15(5): 382-98.

60. Phillips HA, Marini C, Scheffer IE, Sutherland GR, Mulley JC, Berkovic SF. A de novo mutation in sporadic nocturnal frontal lobe epilepsy. Ann Neurol 2000; 48(2): 264-7.

61. Lehesjoki AE, Koskiniemi M, Pandolfo M, Antonelli A, Kyllerman M, Wahlstrom J, et al. Linkage studies in progressive myoclonic epilepsy: Unverricht-Lundborg and Lafora’s diseases. Neurology 1992; 42(8): 1545-50.

62. Serratoa JM, Delgado-Escueta AV, Posada I, Shih S, Drury I, Berciano J, et al. The gene for progressive myoclonic epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet 1995; 4(9): 1657-63.

63. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonic epilepsy. Nat Genet 1998; 20(2): 171-4.

64. Moel SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 2005; 6(3): 107-26.

65. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA (tRNA(Lys)) mutation. Cell 1990; 61(6): 931-7.

66. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005; 6(5): 389-402.

67. Kullmann DM. Genetics of epilepsy. J Neurol Neurosurg Psychiatry 2002; 73(Suppl 2): I12-I35.

68. Guerrini R, Carrozzo R. Epileptogenic brain malformations: clinical presentation, malformative patterns and indications for genetic testing. Seizure 2001; 10(7): 532-43.

69. Corey LA, Pellock JM, Boggs JG, Miller LL, DeLorenzo RJ. Evidence for a genetic predisposition for status epilepticus. Neurology 1998; 50(2): 558-60.

70. Pal DK, Pong AW, Chung WK. Genetic evaluation and counseling for epilepsy. Nat Rev Neurol 2010; 6(8): 445-53.

71. Asadi-Pooya AA. Epilepsy and consanguinity in Shiraz, Iran. Eur J Paediatr Neurol 2005; 9(6): 383-6.

72. Al-Rajeh S, Abomelha A, Awada A, Bademossi O, Ismail H. Epilepsy and other convulsive disorders in Saudi Arabia: a prospective study of 1,000 consecutive cases. Acta Neurol Scand 1990; 82(5): 341-5.

73. Mehndiratta MM, Paul B, Mehndiratta P. Arranged marriage, consanguinity and epilepsy. Neurology Asia 2007; 12(Supplement 1): 15-7.

Epileptic syndromes

Irans J Neurol 2015; 14(1)